Soleno initiates $100M accelerated share repurchase; amends loan facility

SOLENO THERAPEUTICS INC

Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.
Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.
CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback.

item 1.01item 2.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.